NAMPT inhibitor-linker 2 is primarily utilized in the development of targeted cancer therapies. It functions as a key component in antibody-drug conjugates (ADCs), where it links a cytotoxic drug to a monoclonal antibody. This design allows for the precise delivery of the drug to cancer cells, minimizing damage to healthy tissues. The inhibitor specifically targets nicotinamide phosphoribosyltransferase (NAMPT), an enzyme involved in NAD+ biosynthesis, which is crucial for cancer cell survival and proliferation. By disrupting this pathway, it induces cancer cell death. Its application is particularly significant in treating tumors that are resistant to conventional therapies, offering a more targeted and effective approach to cancer treatment.